Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
Study sponsor: Theravance Biopharma
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2026-01Estimated
Enrollment · participants102Estimated
Source updated2025-09-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.